Research programme: adult stem cell therapies - Caladrius Biosciences

Drug Profile

Research programme: adult stem cell therapies - Caladrius Biosciences

Latest Information Update: 04 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NeoStem
  • Developer Caladrius Biosciences; University of Louisville
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Acute radiation syndrome; Cardiovascular disorders; Eye disorders; Musculoskeletal disorders; Neurological disorders; Periodontal disorders; Wounds

Most Recent Events

  • 30 May 2013 Early research in Periodontal disorders in USA (Topical)
  • 25 Jun 2012 NeoStem receives grant from National Institute of Allergy and Infectious Diseases for adult stem cell therapy development in Acute radiation syndrome
  • 25 Jun 2012 Early research in Acute radiation syndrome in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top